公开(公告)号：US20210079103A1

公开(公告)日：2021-03-18

申请号：US16936457

申请日：2020-07-23

申请人： Prothena Biosciences Limited ,  F. Hoffmann-La Roche AG

发明人： Jay Soto ,  Daniel Keith Ness ,  Martin Koller ,  Diane Mould ,  Frank Boess ,  Meret Martin-Facklam ,  Valerie Cosson ,  Hans Peter Grimm ,  Ronald Gieschke ,  Sara Belli ,  Silke Weber

IPC分类号： C07K16/28 ,  A61P25/28 ,  A61P25/16 ,  A61K31/198 ,  A61K9/00 ,  A61B5/00 ,  C07K16/18

摘要： The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.